Immunohistochemical assessment of the diagnostic utility of PD-L1: a preliminary analysis of anti-PD-L1 antibody (SP142) for lymphoproliferative diseases with tumour and non-malignant Hodgkin-Reed-Sternberg (HRS)-like cells-Reference-Cited by-同舟云学术

Immunohistochemical assessment of the diagnostic utility of PD-L1: a preliminary analysis of anti-PD-L1 antibody (SP142) for lymphoproliferative diseases with tumour and non-malignant Hodgkin-Reed-Sternberg (HRS)-like cells

Published:2018-03-09 Issue:7 Volume:72 Page:1156-1163
ISSN:0309-0167
Container-title:Histopathology
language:en
Short-container-title:Histopathology

Author:

Sakakibara Ayako¹²,Kohno Kei¹,Eladl Ahmed E¹³,Klaisuwan Teerada¹⁴^ORCID,Ishikawa Eri¹⁵,Suzuki Yuka¹^ORCID,Shimada Satoko¹,Nakaguro Masato¹^ORCID,Shimoyama Yoshie¹,Takahara Taishi⁶,Kato Seiichi⁷,Asano Naoko⁸^ORCID,Nakamura Shigeo¹,Satou Akira⁶^ORCID

Affiliation:

1. Department of Pathology and Laboratory Medicine; Nagoya University Hospital; Nagoya Japan

2. Department of Pathology; Okazaki City Hospital; Okazaki Japan

3. Department of Pathology; Faculty of Medicine; Mansoura University; Mansoura Egypt

4. Department of Pathology; Faculty of Medicine; Chiang Mai University; Chiang Mai Thailand

5. Department of Gastroenterology and Hepatology; Aichi Medical University Hospital; Nagakute Japan

6. Department of Surgical Pathology; Aichi Medical University Hospital; Nagakute Japan

7. Department of Pathology and Molecular Diagnostics; Aichi Cancer Center Hospital; Nagano Japan

8. Department of Clinical Laboratory; Nagano Prefectural Suzaka Hospital; Nagano Japan

Publisher

Wiley

Subject

General Medicine,Histology,Pathology and Forensic Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/his.13475/fullpdf

Reference25 articles.

1. PD-1 and its ligands in tolerance and immunity;Keir;Annu. Rev. Immunol.,2008

2. Immune checkpoint blockade: the role of PD-1-PD-l axis in lymphoid malignancies;Ilcus;OncoTargets Ther.,2017

3. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies;Chen;Clin. Cancer Res.,2013

4. Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma;Kiyasu;Blood,2015

5. Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas;Kwon;Histopathology,2016

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Frequent expression of PD-L1 in BLS-type diffuse large B-cell lymphoma: implications for aggressiveness and immunotherapy;Pathology;2024-04

2. Expression of the immune checkpoint molecules PD‑L1 and PD‑1 in EBV‑associated lymphoproliferative disorders: A meta‑analysis;Experimental and Therapeutic Medicine;2023-11-10

3. Epstein–Barr virus‐positive monoclonal lymphoplasmacytic proliferation associated with neurosyphilis in an immunocompetent patient: A case report;Neuropathology;2023-07-09

4. Diagnostic Utility of STAT6 and pSTAT6 Immunohistochemistry for Distinguishing Classic Hodgkin Lymphoma and Peripheral T-Cell Lymphoma With Hodgkin and Reed-Sternberg–like Cells;American Journal of Surgical Pathology;2023-05-30

5. Diagnostic approach for classic Hodgkin lymphoma in small samples with an emphasis on PD-L1 expression and EBV harboring in tumor cells: a brief review from morphology to biology;Journal of Clinical and Experimental Hematopathology;2023